We are currently conducting a prospective, open-label clinical trial titled “Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles “ (NCT05810350). Here, EGFR is linked to leptomeningeal metastasis.